XNCR Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of --. Xencor, Inc.'s return on equity of -20.07% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Xencor, Inc. has a consensus price target of $28.00, signalling upside risk potential of 54.36%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1170.25%. Given that GT Biopharma, Inc. has higher upside potential than Xencor, Inc., analysts believe GT Biopharma, Inc. is more attractive than Xencor, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Xencor, Inc.'s net income of -$6M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 8.93x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of -19.69%. Xencor, Inc.'s return on equity of -20.07% beat Moderna, Inc.'s return on equity of -30.18%.

Xencor, Inc. has a consensus price target of $28.00, signalling upside risk potential of 54.36%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Xencor, Inc. has higher upside potential than Moderna, Inc., analysts believe Xencor, Inc. is more attractive than Moderna, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Xencor, Inc.'s net income of -$6M is higher than Moderna, Inc.'s net income of -$200M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 8.93x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nuvalent, Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of --. Xencor, Inc.'s return on equity of -20.07% beat Nuvalent, Inc.'s return on equity of -38.24%.

Xencor, Inc. has a consensus price target of $28.00, signalling upside risk potential of 54.36%. On the other hand Nuvalent, Inc. has an analysts' consensus of $141.82 which suggests that it could grow by 32.72%. Given that Xencor, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Xencor, Inc. is more attractive than Nuvalent, Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Nuvalent, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuvalent, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor, Inc. pays -- of its earnings as a dividend. Nuvalent, Inc. pays out -- of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are larger than Nuvalent, Inc. quarterly revenues of --. Xencor, Inc.'s net income of -$6M is higher than Nuvalent, Inc.'s net income of -$122.4M. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Nuvalent, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 8.93x versus -- for Nuvalent, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -28.7% compared to Xencor, Inc.'s net margin of 21.32%. Xencor, Inc.'s return on equity of -20.07% beat Pfizer Inc.'s return on equity of 10.84%.

Xencor, Inc. has a consensus price target of $28.00, signalling upside risk potential of 54.36%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Xencor, Inc. has higher upside potential than Pfizer Inc., analysts believe Xencor, Inc. is more attractive than Pfizer Inc..

Xencor, Inc. has a beta of 0.960, which suggesting that the stock is 3.97% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Xencor, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Xencor, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Xencor, Inc. quarterly revenues are $21M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Xencor, Inc.'s net income of -$6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Xencor, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor, Inc. is 8.93x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.